DBV Technologies(US:DBVT)2025-10-28 21:40Financial Performance - DBV Technologies reported a net loss of $102.1 million for the nine months ended September 30, 2025, compared to a net loss of $90.9 million for the same period in 2024, representing an increase of 12.9%[7] - Operating expenses increased to $107.0 million for the nine months ended September 30, 2025, up from $96.4 million in the same period of 2024, primarily due to the launch of the COMFORT Toddlers supplemental safety study[5] - The company recorded operating income of $5.0 million for the nine months ended September 30, 2025, compared to $3.6 million for the same period in 2024, reflecting a growth of 38.9%[4] - Research tax credits increased to $5.0 million for the nine months ended September 30, 2025, compared to $3.6 million in 2024, indicating a rise of 38.9%[4] - Net cash flows used in operating activities decreased to $86.0 million for the nine months ended September 30, 2025, from $92.2 million in the same period of 2024, a reduction of 6.7%[18] Cash Position and Financing - Cash and cash equivalents rose to $69.8 million as of September 30, 2025, compared to $32.5 million at the end of 2024, marking a net increase of $37.4 million[9] - The company anticipates that its cash and cash equivalents will be sufficient to fund operations into the third quarter of 2026, based on current plans and assumptions[14] - An equity offering program was established in September 2025, allowing the company to offer American Depositary Shares with an aggregate offering price of up to $150.0 million[13] - The company expects to utilize proceeds from a private placement financing of up to $306.9 million to advance the Viaskin® Peanut patch through Biologics License Application submission and U.S. commercial launch, if approved[10] Future Prospects - The VITESSE Phase 3 study's primary endpoint achievement will trigger an acceleration of warrant exercises, potentially providing up to $181.4 million in gross proceeds[12]